Revolution Medicines to Participate in Upcoming Investor Conferences
Revolution Medicines, Inc. (Nasdaq: RVMD) announced participation in upcoming investor conferences, with CEO Mark A. Goldsmith set to speak at both events.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Revolution Medicines, Inc. (Nasdaq: RVMD) announced participation in upcoming investor conferences, with CEO Mark A. Goldsmith set to speak at both events. The 2022 Wells Fargo Healthcare Conference will take place from September 7-9, featuring Goldsmith's fireside chat on September 8 at 3:45 p.m. Eastern. The H.C. Wainwright 24th Annual Global Investment Conference follows from September 12-14, with a chat scheduled for September 12 at 7:00 a.m. Eastern. A webcast of the latter will be available online for 14 days post-event.
Details
News Market Reaction – RVMD
The recorded move for RVMD in the trading session of this news was +3.74%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that the company will participate in two upcoming investor conferences. Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines, will be the featured speaker in fireside chats at the 2022 Wells Fargo Healthcare Conference and the H.C. Wainwright 24th Annual Global Investment Conference.
Details of these events are as follows:
- 2022 Wells Fargo Healthcare Conference
Conference Date: September 7-9, 2022
Fireside Chat Time/Date: 3:45 – 4:15 p.m. Eastern on Thursday, September 8, 2022
Format: In-person conference located at Encore Boston Harbor
- H.C. Wainwright 24th Annual Global Investment Conference
Conference Date: September 12-14, 2022
Fireside Chat Time/Date: 7:00 a.m. Eastern on Monday, September 12, 2022
Format: Hybrid event (in-person and virtual); webcast available
A webcast of the H.C. Wainwright fireside chat can be accessed at: https://ir.revmed.com/events-and-presentations. An archived replay of the webcast will be available on the investors section of the company’s website for at least 14 days following the event.
About Revolution Medicines, Inc.
Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. The company’s RAS(ON) Inhibitors RMC-6236 (RASMULTI) and RMC-6291(KRASG12C) are in clinical development. Additional RAS(ON) Inhibitors in development include RMC-9805 (KRASG12D) and RMC-8839 (KRASG13C), and a pipeline of research compounds targeting additional RAS variants. RAS Companion Inhibitors in clinical development include RMC-4630 (SHP2) and RMC-5552 (mTORC1/4EBP1).
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.